

# Asthma – Pipeline Assessment and Insights

Reference No.: **PSRCXXXGPR**

Publication Date: **April 2018**

## **Table of Contents**

### **1.1 List of Tables**

### **1.2 List of Figures**

## **2 Asthma Disease**

### **2.1 Disease Overview**

- 2.1.1 Disease Definition
- 2.1.2 Disease Epidemiology
- 2.1.3 Current Treatment Options
- 2.1.4 Key unmet needs

## **3 Pipeline Assessment**

### **3.1 Overview**

### **3.2 Strategic Review of the Pipeline**

### **3.3 Pipeline analysis by Phases of Development**

- 3.3.1 NDA/BLA Filed
- 3.3.2 Phase III Pipeline
- 3.3.3 Phase II Pipeline
- 3.3.4 Phase I Pipeline
- 3.3.5 Preclinical Pipeline
- 3.3.6 Discovery Pipeline

### **3.4 Pipeline Analysis by Mechanism of Action**

### **3.5 Pipeline Analysis by Novelty of Mechanism of Action**

### **3.6 Suspended and Terminated products**

### **3.7 Asthma – Promising Therapies in Pipeline**

- 3.7.1 Trelegy Ellipta
  - 3.7.1.1 Overview
  - 3.7.1.2 Research & Development Key Milestones
  - 3.7.1.3 Efficacy
  - 3.7.1.4 Safety
  - 3.7.1.5 Dosing Frequency and Formulation
  - 3.7.1.6 Potential Clinical Positioning
  - 3.7.1.7 Potential Commercial Positioning
  - 3.7.1.8 Pricing and Reimbursement

### 3.7.2 Trimbow

- 3.7.2.1 Overview
- 3.7.2.2 Research and development key milestones
- 3.7.2.3 Efficacy
- 3.7.2.4 Safety
- 3.7.2.5 Dosing Frequency and Formulation
- 3.7.2.6 Potential Clinical Positioning
- 3.7.2.7 Potential Commercial Positioning
- 3.7.2.8 Pricing and Reimbursement

### 3.7.3 Dupixent

- 3.7.3.1 Overview
- 3.7.3.2 Research and development key milestones
- 3.7.3.3 Efficacy
- 3.7.3.4 Safety
- 3.7.3.5 Dosing Frequency and Formulation
- 3.7.3.6 Potential Clinical Positioning
- 3.7.3.7 Potential Commercial Positioning
- 3.7.3.8 Pricing and Reimbursement

### 3.7.4 QVM149

- 3.7.4.1 Overview
- 3.7.4.2 Research and development key milestones
- 3.7.4.3 Efficacy
- 3.7.4.4 Safety
- 3.7.4.5 Dosing Frequency and Formulation
- 3.7.4.6 Potential Clinical Positioning
- 3.7.4.7 Potential Commercial Positioning
- 3.7.4.8 Pricing and Reimbursement

### 3.7.5 PT010

- 3.7.5.1 Overview
- 3.7.5.2 Research and development key milestones
- 3.7.5.3 Efficacy
- 3.7.5.4 Safety
- 3.7.5.5 Dosing Frequency and Formulation
- 3.7.5.6 Potential Clinical Positioning
- 3.7.5.7 Potential Commercial Positioning
- 3.7.5.8 Pricing and Reimbursement

### 3.7.6 Tralokinumab

- 3.7.6.1 Overview
- 3.7.6.2 Research and development key milestones
- 3.7.6.3 Efficacy

## Table of Contents

- 3.7.6.4 Safety
- 3.7.6.5 Dosing Frequency and Formulation
- 3.7.6.6 Potential Clinical Positioning
- 3.7.6.7 Potential Commercial Positioning
- 3.7.6.8 Pricing and Reimbursement
- 3.7.7 QAW039 (Fevipirant)
  - 3.7.7.1 Overview
  - 3.7.7.2 Research and development key milestones
  - 3.7.7.3 Efficacy
  - 3.7.7.4 Safety
  - 3.7.7.5 Dosing Frequency and Formulation
  - 3.7.7.6 Potential Clinical Positioning
  - 3.7.7.7 Potential Commercial Positioning
  - 3.7.7.8 Pricing and Reimbursement
- 3.7.8 MK-1029
  - 3.7.8.1 Overview
  - 3.7.8.2 Research and development key milestones
  - 3.7.8.3 Efficacy
  - 3.7.8.4 Safety
  - 3.7.8.5 Dosing Frequency and Formulation
  - 3.7.8.6 Potential Clinical Positioning
  - 3.7.8.7 Potential Commercial Positioning
  - 3.7.8.8 Pricing and Reimbursement
- 3.7.9 QMF 149
  - 3.7.9.1 Overview
  - 3.7.9.2 Research and development key milestones
  - 3.7.9.3 Efficacy
  - 3.7.9.4 Safety
  - 3.7.9.5 Dosing Frequency and Formulation
  - 3.7.9.6 Potential Clinical Positioning
  - 3.7.9.7 Potential Commercial Positioning
  - 3.7.9.8 Pricing and Reimbursement

## **4 Appendix**

- 4.1 Coverage**
- 4.2 Methodology and Research conducted**
- 4.3 About Pharmascroll**
- 4.4 Contact Us**
- 4.5 Disclaimer**